Table 3.

Estimated pancreatic cancer SIRs for BRCA1 and BRCA2 mutation carriers from the BCFR

BRCA1 mutation carriersBRCA2 mutation carriers
ObsExpSIR (95% CI)ObsExpSIR (95% CI)
Overall34.08.264.11 (2.94—5.76)41.87.235.79 (4.28–7.84)
Men14.84.793.09 (1.86–5.15)22.53.885.81 (3.84–8.78)
Women19.23.475.52 (3.53–8.64)19.33.355.77 (3.69–9.01)
≤50 y5.590.727.75 (3.38–17.7)5.470.559.90 (4.28–22.9)
>50 y28.47.543.77 (2.61–5.44)36.46.685.45 (3.94–7.54)
FDRs11.22.514.47 (2.49–8.03)13.62.455.55 (3.27–9.45)
Population-based5.882.192.68 (1.20–6.02)11.52.255.12 (2.88–9.12)
Clinic-based28.16.074.63 (3.20–6.70)30.34.986.09 (4.27–8.70)
≤2 BCs13.83.314.18 (2.47–7.08)24.22.708.98 (6.03–13.4)
≥3 BCs20.14.954.07 (2.63–6.30)17.64.523.90 (2.44–6.21)

Abbreviations: BC, breast cancer; Exp, expected number of cases; Obs, observed number of cases.